Some Blood Pressure Drugs May Ups Pancreatic Cancer’s Development Risk in Women

Some blood pressure drugs may ups pancreatic cancer’s development risk in women, new research suggests. Some women who treat their high blood pressure with certain prescribed drugs are more likely to develop pancreatic cancer than those who use other meds.


According to a study presented at American Association for Cancer Research Annual Meeting, calcium channel blockers are linked with increased risk for pancreatic cancer among woman. It states that Some blood pressure drugs may ups pancreatic cancer’s development risk.  Pancreatic cancer commonly occurs among older individuals suffering chronic comorbid medical conditions like hypertension.

Zhensheng Wang, Ph.D., postdoctoral associate at Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine and colleagues conducted the current study by collecting data from the Women’s Health Initiative.

They followed more than 145,000 participants aged 50 to 79 years in the Women’s Health Initiative study. They monitored their medication use from the year 1993 to 1998. The study analyzed four types of antihypertensive drugs including blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, and beta blockers.

The study found that people who used the drugs three years or more demonstrated a 107% higher risk of developing pancreatic cancer than those who took other blood pressure drugs.

“Our findings on short-acting calcium channel blocker use and pancreatic cancer risk are a novel and of potential broad medical and public health significance if confirmed,” Wang said. “Short-acting calcium channel blockers are still prescribed to manage hypertension, which is one of the components of metabolic syndrome, and metabolic syndrome is a possible risk factor for pancreatic cancer,” he added.